A6 Peptide Paclitaxel Combination Therapy Ovarian Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ovarian cancer, particularly those involving paclitaxel, face challenges in inhibiting metastasis due to resistance and recurrence, as they fail to effectively target the subpopulation of highly invasive tumorigenic cells expressing CD44.
Innovation Solution
Combining a CD44-modulating polypeptide, such as those with sequences Ac-KPSSPPEE-NH2 or Ac-NASAPPEE-NH2, with paclitaxel to inhibit metastasis by restoring sensitivity and enhancing the anti-cancer activity of paclitaxel in ovarian cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If paclitaxel is used to treat ovarian cancer, then anti-cancer activity is achieved, but resistance and recurrence occur due to inability to target CD44-expressing tumorigenic cells
Solution Approach 1:
The patent combines paclitaxel with a CD44-modulating polypeptide (A6) to create a dual-function treatment regimen. The polypeptide specifically targets CD44-expressing tumorigenic cells while paclitaxel provides broad anti-cancer activity, together addressing both the need for targeted therapy and general anti-cancer efficacy to prevent resistance and recurrence
Solution Approach 2:
The CD44-modulating polypeptide acts as an intermediary that specifically binds to and modulates CD44 receptors on tumorigenic cells. This intermediary component enables selective targeting of the problematic CD44-expressing cell population that paclitaxel alone cannot effectively address, thereby preventing resistance and recurrence
2Productivity
If conventional therapy is used, then treatment is administered, but metastatic activity is not effectively inhibited
Solution Approach 1:
The patent applies local quality by using the CD44-modulating polypeptide to specifically target and modify the properties of CD44-expressing tumorigenic cells. This localized modulation of CD44 activity in the specific cell population responsible for metastasis enhances overall treatment efficacy while specifically addressing the metastatic threat
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
Provided herein are therapeutic combinations of A6 peptide (SEQ ID NO: 1) and more anti-cancer agents, radiation therapy, or a combination thereof and the use of such combinations in the treatment of cancer.